Get started
Author

Reshmi Nair

ORCID: 0000-0002-5222-2882
Observed ORCID: 0000-0002-5222-2882
OpenAlex ID: A5073479259
T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab
2017 · Usha Bughani, Arindam Saha, et al. · PLoS ONE · 55
BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth
2023 · Srinivas Reddy Boreddy, Reshmi Nair, et al. · Cancer Research · 40
PDF
874 Development of BCA101, a bifunctional antibody capable of simultaneously disabling EGFR and TGFβ signaling, as novel single-agent immunotherapy
2021 · Srinivas Reddy Boreddy, Reshmi Nair, et al. · Journal for ImmunoTherapy of Cancer · 3
PDF
Correction: T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab
2018 · Usha Bughani, Arindam Saha, et al. · PLoS ONE · 3
PDF
Characterization and similarity assessment of a pegfilgrastim biosimilar MYL-1401H.
2018 · Praveen Kallamvalliillam Sankaran, Dinesh V. Palanivelu, et al. · Journal of Clinical Oncology · 2
Abstract 4434: Ficerafusp alfa reverses acquired resistance to the KRAS-G12C inhibitor sotorasib in KRAS-G12C-mutated lung tumors
2025 · Veena Somasundaram, Shiv Ram Krishn, et al. · Cancer Research · 1
Supplementary Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth
2025 · Srinivas Reddy Boreddy, Reshmi Nair, et al.
1180 Dual targeting of TGF-β and EGFR with ficerafusp alfa shows superior anti-tumor activity over cetuximab in KRAS/BRAF wild-type MSS colorectal cancer
2025 · Anshu Kuriakose, Reshmi Nair, et al. · Journal for ImmunoTherapy of Cancer
PDF
Supplementary Data from BCA101 is a Tumor-Targeted Bifunctional Fusion Antibody that Simultaneously Inhibits EGFR and TGF-β Signalling to Durably Suppress Tumor Growth
2024 · Srinivas Reddy Boreddy, Reshmi Nair, et al.
Data from BCA101 is a Tumor-Targeted Bifunctional Fusion Antibody that Simultaneously Inhibits EGFR and TGF-β Signalling to Durably Suppress Tumor Growth
2024 · Srinivas Reddy Boreddy, Reshmi Nair, et al.
Supplementary Data from BCA101 is a Tumor-Targeted Bifunctional Fusion Antibody that Simultaneously Inhibits EGFR and TGF-β Signalling to Durably Suppress Tumor Growth
2024 · Srinivas Reddy Boreddy, Reshmi Nair, et al.
1426 Combination with BCA101 improves the efficacy of KRAS-G12C inhibitor and overcomes G12C inhibitor-induced resistance in lung and colon cancer cell lines
2023 · Reshmi Nair, Veena Somasundaram, et al. · Journal for ImmunoTherapy of Cancer
PDF
Supplementary Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth
2023 · Srinivas Reddy Boreddy, Reshmi Nair, et al.
Real world outcomes of next generation sequencing (NGS) of progressive RAI resistant metastatic thyroid cancer and treatment of these patients with redifferentiation protocol.
2023 · Jennifer Wheeley, Nikita Chintapally, et al. · Journal of Clinical Oncology
Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth
2023 · Srinivas Reddy Boreddy, Reshmi Nair, et al.
Supplementary Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth
2023 · Srinivas Reddy Boreddy, Reshmi Nair, et al.
Abstract 1864: An improved trispecific antibody (TsAb) platform for optimally engaging T cells for the treatment of solid tumor malignancies
2023 · Reshmi Nair, Veena Somasundaram, et al. · Cancer Research
Works count: 17
Citation count: 104
H-index: 3
I10-index: 2
Year
Topic
Type